Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP2C19 genotype-guided antiplatelet therapy after primary PCI for STEMI
NL-OMON47500Phase 4Active, not recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clopidogrel, prasugrel and ticagrelor in myocardial infarction (MI) (2 arms), sponsored by St. Antonius Ziekenhuis. Primary endpoints: Net clinical outcome composite at 1 year, Bleeding composite superiority and 1 more. Started Jun 2011; status: active, not recruiting.
02
Drugs
clopidogrelprasugrelticagrelor
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON47500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47500.